Clovis Oncology, Inc.

DUBLIN--( BUSINESS WIRE )--The "Ovarian Cancer Market by Type, by Diagnosis Scans, by Treatment, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering. The comprehensive analysis of the global ovarian cancer market reveals a promising trajectory for the industry, with projections estimating a compound annual growth rate (CAGR) of 23.53% over the forecast period from 2024 to 2034. At the forefront of this growth is the escalation in the prevalence of ovarian cancer, supported by significant advancements in diagnosis methods and treatment protocols. Rise in Ovarian Cancer Incidence Fuels Market Expansion With ovarian cancer ranking as one of the most lethal gynecological malignancies worldwide, there is an urgent demand for enhanced diagnostic and therapeutic options. The market's expansion is bolstered by factors such as an aging global population, shifting lifestyle habits, and increased exposure to environmental risks. These factors are contributing to the projected growth of the market, as stakeholders across the globe rally to provide more effective solutions in combating this pervasive disease. Diagnostic Innovations Elevate Early Detection Rates Innovation in diagnostic technologies plays a critical role in managing ovarian cancer outcomes. Early-stage detection is paramount, as it significantly increases patient survival rates. Market analysis indicates a shift towards specialized imaging modalities, including MRI, CT, and ultrasound scans, as well as the emergence of breakthrough biomarkers and genetic testing capabilities. These developments not only facilitate early diagnosis but also tailor treatment approaches to the individual needs of patients, thereby enhancing the effectiveness of interventions. Advancements in Chemotherapy and Targeted Therapies Propel Treatment Segment Chemotherapy remains a cornerstone in the treatment of ovarian cancer, capturing a significant portion of the market revenue. As a testament to the ongoing evolution in this arena, there has been a surge in approvals for drugs indicated for advanced stages of the disease, pointing to a sustained commitment in refining chemotherapy protocols. Concurrently, the targeted therapy segment is anticipated to expand rapidly, driven by the precision and potency of therapies such as PARP inhibitors that are emerging as a game-changer, especially for patients with specific genetic profiles. Hospitals Dominate End-User Segment with Complete Care Facilities Hospitals are the primary setting for ovarian cancer treatment, offering a full spectrum of services, from surgical intervention to post-operative care. This end-user segment commands a significant portion of the market due to the comprehensive nature of care necessary for ovarian cancer patients. Meanwhile, diagnostic centers emerge as rapidly growing entities within the market, reflecting the increased need for specialized radiological and diagnostic evaluations crucial for precise staging and treatment planning. North America Leads Revenue Share as Asia Pacific Emerges with Robust Growth North America continues to dominate the global ovarian cancer market, driven by superior healthcare infrastructure, a high prevalence of ovarian cancer, and swift adoption of novel treatment methodologies. However, the Asia Pacific region is anticipated to experience the fastest growth rate during the forecast period. This can be attributed to the growing public health initiatives, enhanced access to medical care, and burgeoning research partnerships that are significantly shaping the healthcare landscape in Asia Pacific nations. The ovarian cancer market's projected growth reflects ongoing global efforts to address the complex challenges posed by this formidable disease, and it highlights the relentless pursuit of advancements in medical science and healthcare delivery. As the market navigates toward 2034, these trends signal a new era of hope for patients affected by ovarian cancer around the world. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2023 - 2034 Estimated Market Value (USD) in 2023 $3.06 Billion Forecasted Market Value (USD) by 2034 $31.31 Billion Compound Annual Growth Rate 23.5% Regions Covered Global Companies Featured AstraZeneca Roche Holdings Johnson & Johnson Merck & Co. Inc. Bristol Myers Squibb GlaxoSmithKline plc Pfizer Inc. AbbVie Inc. Novartis AG Eisai Co. Ltd. TESARO (a GSK company) Clovis Oncology Genentech Inc. (a member of the Roche Group) Takeda Pharmaceutical Company Limited Amgen Inc. For more information about this report visit https://www.researchandmarkets.com/r/gakswh About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

On May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Efficacy was investigated in TRITON2 (NCT02952534), an ongoing, multi-center, single arm clinical trial in 115 patients with BRCA-mutated (germline and/or somatic) mCRPC who had been treated with androgen receptor-directed therapy and taxane-based chemotherapy. Patients received rucaparib 600 mg orally twice daily and concomitant GnRH analog or had prior bilateral orchiectomy. Objective response rate (ORR) and duration of response (DOR) were assessed in 62 patients with measurable disease. The confirmed ORR was 44% (95% CI: 31, 57). Median DOR was not evaluable (NE; 95% CI: 6.4, NE). The range for the DOR was 1.7-24+ months. Fifteen of the 27 (56%) patients with confirmed objective responses had a DOR of ≥6 months. The most common adverse reactions (≥ 20%) among all 115 patients with BRCA-mutated mCRPC were fatigue, nausea, anemia, increased ALT/AST, decreased appetite, rash, constipation, thrombocytopenia, vomiting, and diarrhea. The recommended rucaparib dose is 600 mg orally twice daily with or without food. Patients receiving rucaparib for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. View full prescribing information for RUBRACA. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Rucaparib previously was granted Breakthrough Therapy designation for this indication. This application was granted priority review. A description of FDA expedited programs is in the Guidance for Industry: Expedited Programs for Serious Conditions-Drugs and Biologics. Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System or by calling 1-800-FDA-1088. For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate at 240-402-0004 or email OncProjectFacilitate@fda.hhs.gov. For information on the COVID-19 pandemic, see the following resources: FDA: Coronavirus Disease 2019 (COVID-19) NCI: Coronavirus: What People With Cancer Should Know CDC: Coronavirus (COVID-19) Follow the Oncology Center of Excellence on Twitter @FDAOncologyExternal Link Disclaimer.

AstraZeneca also has a new PARP inhibitor in early trials that could help boost future lagging sales from Lynparza when it starts to lose patent protection in 2028. AstraZeneca and Merck & Co. were the first to grab an FDA approval for their PARP inhibitor Lynparza, and, despite growing competition, the drug is set to remain top dog in the PARP space. That’s according to a new report out by analysts at GlobalData, which predicts $4 billion in global sales for Lynparza by 2027, boosted by new licenses. Lynparza (olaparib) was first approved for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who had already been given three lines or more of chemo back in 2014. Since then, it has racked up supplemental U.S. nods in various cancers, including in certain breast, prostate, pancreatic and ovarian tumors. GlobalData sees the drug’s revenues in these indications to reach “over 68% of the global PARP inhibitors market by 2027,” helping bring in that $4 billion. Most of Lynparza's sales come from ovarian and HER2-negative breast cancer treatment, the analysts said in their latest report. It doesn’t have the market to itself, however, with GSK’s PARP inhibitor Zejula (niraparib) holding the second position, with more than $1.6 billion in sales and 28% of the market share. The drug, which was originally developed by Tesaro before being bought out by GSK, saw its first approval in 2017 for ovarian cancer. It has since added several new licenses within that disease space. It’s not all been positive for Lynparza and PARPs, however. AZ and Merck back in the fall of 2022 voluntarily pulled the drug from treating heavily pretreated ovarian cancer patients, after seeing a potential “detrimental effect” on patient survival from a confirmatory phase 3 trial. GSK and Clovis Oncology, for its drug Rubraca, had also pulled their drugs in the same patient population. Rubraca has seen the hardest path, with Clovis a year back selling off the PARP drug in a bankruptcy sale to a Swiss pharma. The drug never really picked up after its approval in 2016 and has been the weak link in the PARP market. For Lynparza and Zejula, however, the withdrawals did not cause much of a sales impact, given that the drugs have largely moved into earlier treatment settings. And, while Lynparza will be making strong blockbuster sales in 2027, patent protection in the U.S. falls off in 2028. From then on, “there is an anticipated downshift in sales post-patent expiry through generic erosion,” said  Biswajit Podder, Ph.D., oncology and hematology analyst at GlobalData. But there is hope on the horizon. Lynparza currently has 123 ongoing phase clinical trials across a multitude of cancer types and combos, which GlobalData says “signifies its pivotal role in oncology.” AZ is also working on an experimental selective PARP1 inhibitor, saruparib, which has shown some early promise in phase 1/2 trials for homologous recombination repair (HRR)-deficient advanced breast cancers. “If approved, saruparib would further strengthen AstraZeneca’s lead in the PARP inhibitor market,” Podder said.